Lumipulse® G CEA-N (Carcinoembryonic Antigen)
Immunoreaction cartridges for in vitro diagnostic (IVD) use with the LUMIPULSE G System for the quantitative measurement of carcinoembryonic antigen (CEA) in serum or plasma.
The assay utilises proven CLEIA (ChemiLuminescent Enzyme Immunoassay) technology with results that are available in up to 35 minutes.
Product number 292662
-
Details
Assay technology
CLEIA - ChemiLuminescent Enzyme Immunoassay
See the LUMIPULSE G1200 working in this video:
-
Documentation
Browse regulatory documents for this product
Create a (free!) eServices account and start browsing all regulatory documentation right away.
Other documents
FileLumipulse G Lung Disease Management brochure.pdf (pdf, 151.32 kb)Get access to this section and more
Create a free eServices account now and instantly access multiple digital resources:
- Regulatory product documentation
- Selected scientific posters
- Product leaflets
- How-to videos and more…
-
Insights
Can KL-6 be a specific marker of alveolar damage for COVID-19 patients?
There are many reference centers across Europe that have included KL-6 as one of the biomarkers within the COVID-19 protocol to strengthen the battery...
Apr 30, 2020
From Classification to disease activity
While IPF is the classic fibrosing ILD, clinical data suggest that there is a larger group of patients with differing clinical ILD diagnoses who...
Dec 17, 2019
Recent research has shown that serum and bronchoalveolar lavage fluid level of KL-6 has an important value in the diagnosis, treatment assessment and...
Dec 2, 2019
-
Related products
-
Product inquiry
